TY - CHAP M1 - Book, Section TI - Pancreatic Cancer A1 - Mizrahi, Jonathan D. A1 - Maitra, Anirban A1 - Wolff, Robert A. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. A2 - Rieber, Alyssa G. PY - 2022 T2 - The MD Anderson Manual of Medical Oncology, 4e AB - KEY CONCEPTSPancreatic cancer has a five-year survival of 10%, and it is expected to become the second leading cause of cancer death in the United States by 2030.Modifiable risk factors for pancreatic cancer include tobacco use, obesity, diabetes mellitus (particularly new-onset diabetes), and chronic pancreatitis. Age and family history are well-established, nonmodifiable risk factors.KRAS mutations and p16 inactivation are near universal genomic events identified in pancreatic cancers, and histologically, pancreatic adenocarcinomas are characterized by a dense, collagenous stroma.High-quality multidetector computed tomography imaging is the gold-standard diagnostic and staging modality, because it can classify pancreatic cancers as resectable, borderline resectable, locally advanced, or metastatic.The only potentially curative treatment for pancreatic cancer is surgical resection, which is an option for only 15% to 20% of patients, because most patients are diagnosed at an advanced stage.Recent advances in combination chemotherapy, particularly FOLFIRINOX and gemcitabine plus nab-paclitaxel, have increased survival for patients with advanced pancreatic cancer; FOLFIRINOX also improves survival in the adjuvant setting.Precision medicine is slowly emerging in pancreatic cancer SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1190835285 ER -